Yoshiko Ueno1, Mitsuru Takeuchi2, Tsutomu Tamada3, Keitaro Sofue4, Satoru Takahashi5, Yuki Kamishima6, Nobuyuki Hinata7, Kenichi Harada7, Masato Fujisawa7, Takamichi Murakami4. 1. Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.. Electronic address: yoshiu0121@gmail.com. 2. Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.; Department of Radiology, Radiolonet Tokai, Nagoya, Japan. 3. Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.; Department of Radiology, Kawasaki Medical School, Kurashiki, Japan. 4. Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan. 5. Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.; Imaging Research Center, Takatsuki General Hospital, Takatsuki, Japan. 6. Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.; Department of Radiology, Nagoya City West Medical Center, Nagoya, Japan. 7. Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Abstract
A Vesical Imaging-Reporting and Data System (VI-RADS) based on multiparametric magnetic resonance imaging (mp-MRI) was developed to provide accurate information for the diagnosis of muscle-invasive bladder cancers (MIBCs). In this study we evaluated the interobserver agreement and diagnostic performance of VI-RADS. We retrospectively evaluated data for 74 consecutive patients with bladder cancer who had undergone mp-MRI before transurethral resection in a single institution from January 2010 to August 2018. Five readers assessed the probability of the presence of MIBC using VI-RADS scores. The interobserver agreement was assessed by measuring intraclass correlation coefficients (ICCs). Receiver operating characteristic (ROC) analysis was used to evaluate the MIBC diagnostic performance. The area under the ROC curve (AUC) was estimated for ordinal score assessments. Our study demonstrated that interobserver agreement was excellent among five readers (ICC 0.85, 95% confidence interval 0.80-0.89) and the diagnostic performance of VI-RADS was represented as a pooled AUC of 0.90 (95% confidence interval 0.87-0.93). PATIENT SUMMARY: We evaluated the interobserver agreement and diagnostic performance of a new scoring system based on magnetic resonance imaging called a Vesical Imaging-Reporting and Data System (VI-RADS) for muscle-invasive bladder cancer. Our results indicate that VI-RADS is suitable as a comprehensive tool for appropriate treatment planning for patients with bladder cancer.
A Vesical Imaging-Reporting and Data System (VI-RADS) based on multiparametric magnetic resonance imaging (mp-MRI) was developed to provide accurate information for the diagnosis of muscle-invasive bladder cancers (MIBCs). In this study we evaluated the interobserver agreement and diagnostic performance of VI-RADS. We retrospectively evaluated data for 74 consecutive patients with bladder cancer who had undergone mp-MRI before transurethral resection in a single institution from January 2010 to August 2018. Five readers assessed the probability of the presence of MIBC using VI-RADS scores. The interobserver agreement was assessed by measuring intraclass correlation coefficients (ICCs). Receiver operating characteristic (ROC) analysis was used to evaluate the MIBC diagnostic performance. The area under the ROC curve (AUC) was estimated for ordinal score assessments. Our study demonstrated that interobserver agreement was excellent among five readers (ICC 0.85, 95% confidence interval 0.80-0.89) and the diagnostic performance of VI-RADS was represented as a pooled AUC of 0.90 (95% confidence interval 0.87-0.93). PATIENT SUMMARY: We evaluated the interobserver agreement and diagnostic performance of a new scoring system based on magnetic resonance imaging called a Vesical Imaging-Reporting and Data System (VI-RADS) for muscle-invasive bladder cancer. Our results indicate that VI-RADS is suitable as a comprehensive tool for appropriate treatment planning for patients with bladder cancer.
Authors: V Hechler; M Rink; D Beyersdorff; M Beer; A J Beer; V Panebianco; M Pecoraro; C Bolenz; G Salomon Journal: Urologe A Date: 2019-12 Impact factor: 0.639
Authors: Sungmin Woo; Valeria Panebianco; Yoshifumi Narumi; Francesco Del Giudice; Valdair F Muglia; Mitsuru Takeuchi; Soleen Ghafoor; Bernard H Bochner; Alvin C Goh; Hedvig Hricak; James W F Catto; Hebert Alberto Vargas Journal: Eur Urol Oncol Date: 2020-03-19
Authors: Francesco Del Giudice; Rocco Simone Flammia; Martina Pecoraro; Marco Moschini; David D'Andrea; Emanuele Messina; Lucia Martina Pisciotti; Ettore De Berardinis; Alessandro Sciarra; Valeria Panebianco Journal: World J Urol Date: 2022-03-16 Impact factor: 3.661
Authors: Thaisa Gvozdenovic Medina Bricio; Gabriel Lion Gouvea; Rafael Vasconcelos Barros; Fernando Chahud; Jorge Elias; Rodolfo B Reis; Valdair F Muglia Journal: Cancer Imaging Date: 2022-05-03 Impact factor: 5.605